Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced inducement grants for new employees. The Compensation Committee approved non-qualified stock options to purchase 2,100 shares on July 8, 2025.
The grants, made under Aligos' 2024 Inducement Plan, will vest over four years, with 25% vesting after the first year and the remainder vesting monthly. The exercise price equals the closing price of Aligos' common stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are exclusively for new hires.
Aligos Therapeutics (Nasdaq: ALGS), una societ脿 biofarmaceutica in fase clinica specializzata in terapie per malattie epatiche e virali, ha annunciato concessioni di incentivi per i nuovi dipendenti. Il Comitato per la Retribuzione ha approvato opzioni azionarie non qualificate per l'acquisto di 2.100 azioni l'8 luglio 2025.
Le concessioni, effettuate nell'ambito del Piano di Incentivazione 2024 di Aligos, matureranno in un periodo di quattro anni, con il 25% che matura dopo il primo anno e il resto che matura mensilmente. Il prezzo di esercizio corrisponde al prezzo di chiusura delle azioni ordinarie di Aligos alla data di concessione. Queste concessioni sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) e sono riservate esclusivamente ai nuovi assunti.
Aligos Therapeutics (Nasdaq: ALGS), una compa帽铆a biofarmac茅utica en etapa cl铆nica especializada en terapias para enfermedades hep谩ticas y virales, ha anunciado concesiones de incentivos para nuevos empleados. El Comit茅 de Compensaci贸n aprob贸 opciones sobre acciones no calificadas para comprar 2,100 acciones el 8 de julio de 2025.
Las concesiones, realizadas bajo el Plan de Incentivos 2024 de Aligos, se consolidar谩n durante cuatro a帽os, con un 25% consolidado despu茅s del primer a帽o y el resto consolid谩ndose mensualmente. El precio de ejercicio equivale al precio de cierre de las acciones ordinarias de Aligos en la fecha de concesi贸n. Estas concesiones cumplen con la Regla de Cotizaci贸n Nasdaq 5635(c)(4) y son exclusivamente para nuevos empleados.
Aligos Therapeutics (雮橃姢雼�: ALGS)電� 臧� 氚� 氚旍澊霟姢 歆堩櫂 旃橂鞝滊ゼ 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 鞝滌暯 須岇偓搿�, 鞁犾瀰 靷洂 鞙犾箻毳� 鞙勴暅 鞚胳劶韹半笇 欤检嫕 鞓奠厴鞚� 氚滍憸頄堨姷雼堧嫟. 氤挫儊 鞙勳洂須岆姅 2025雲� 7鞗� 8鞚检棎 2,100欤�鞚� 牍勳瀽瓴� 欤检嫕 毵れ垬 鞓奠厴鞚� 鞀轨澑頄堨姷雼堧嫟.
鞚� 鞚胳劶韹半笇電� Aligos鞚� 2024云� 鞙犾澑 瓿勴殟鞐� 霐半澕 攵�鞐悩氅�, 4云�鞐� 瓯胳硱 甓岆Μ臧� 旆摑霅橂┌ 觳� 頃� 頉� 25%臧� 旆摑霅橁碃 雮橂ǜ歆�電� 毵れ洈 旆摑霅╇媹雼�. 頄夓偓 臧�瓴╈潃 攵�鞐澕鞚� Aligos 氤错喌欤� 膦呹皜鞕� 霃欖澕頃╇媹雼�. 鞚� 鞚胳劶韹半笇電� 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)毳� 欷�靾橅晿氅� 鞁犾瀰 靷洂鞐愱矊毵� 鞝侅毄霅╇媹雼�.
Aligos Therapeutics (Nasdaq : ALGS), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les th茅rapies des maladies h茅patiques et virales, a annonc茅 des attributions d'incitation pour les nouveaux employ茅s. Le comit茅 de r茅mun茅ration a approuv茅 des options d'achat d'actions non qualifi茅es pour acqu茅rir 2 100 actions le 8 juillet 2025.
Les attributions, effectu茅es dans le cadre du Plan d'incitation 2024 d'Aligos, seront acquises sur une p茅riode de quatre ans, avec 25 % acquis apr猫s la premi猫re ann茅e et le reste acquis mensuellement. Le prix d'exercice correspond au cours de cl么ture de l'action ordinaire d'Aligos 脿 la date d'attribution. Ces attributions sont conformes 脿 la r猫gle de cotation Nasdaq 5635(c)(4) et sont exclusivement destin茅es aux nouvelles recrues.
Aligos Therapeutics (Nasdaq: ALGS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien f眉r Leber- und Viruskrankheiten spezialisiert hat, hat Anreizzuteilungen f眉r neue Mitarbeiter angek眉ndigt. Der Verg眉tungsausschuss genehmigte am 8. Juli 2025 nicht qualifizierte Aktienoptionen zum Kauf von 2.100 Aktien.
Die Zuteilungen, die im Rahmen des Aligos Inducement Plans 2024 erfolgen, werden 眉ber vier Jahre unverfallbar, wobei 25 % nach dem ersten Jahr und der Rest monatlich unverfallbar werden. Der Aus眉bungspreis entspricht dem Schlusskurs der Stammaktien von Aligos am Zuteilungsdatum. Diese Zuteilungen entsprechen der Nasdaq-Listingregel 5635(c)(4) und sind ausschlie脽lich f眉r Neueinstellungen bestimmt.
- Stock options granted as retention tool for new talent
- Four-year vesting schedule promotes long-term employee retention
- Potential future dilution for existing shareholders
SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, 鈥淎ligos鈥�, 鈥淐ompany鈥�), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company鈥檚 Board of Directors granted non-qualified stock options to purchase an aggregate of 2,100 shares of the Company鈥檚 stock (the 鈥淚nducement Grant鈥�) to newly hired employees on July 8, 2025 (the 鈥淕rant Date鈥�), in connection with the commencement of employment.
The Inducement Grants were granted pursuant to Aligos鈥� 2024 Inducement Plan (the 鈥淧lan鈥�) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.
The Inducement Grants have an exercise price per share equal to the closing price of Aligos鈥� common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered 鈥渇orward-looking statements,鈥� including without limitation, statements regarding Aligos鈥� mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos鈥� clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos鈥� Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
FAQ
What inducement grants did Aligos Therapeutics (ALGS) announce on July 11, 2025?
How will the Aligos Therapeutics (ALGS) inducement grants vest?
What is the exercise price for Aligos Therapeutics (ALGS) inducement grants?
Why did Aligos Therapeutics (ALGS) issue these inducement grants?
